ERBB2 and breast carcinoma: In conclusion, changes in ESR1 and HER2 expression from primary tumor to metastasis have clearly established that breast cancer is an evolving disease and, not surprisingly, the use of CTCs to monitor treatment response on a molecular level has gained increased attention during the last few years.